Huilai Lv

机构：Hebei Medical University, Fourth Hospital of Hebei Medical University, Hebei Science and Technology Department, Hebei University · ORCID：0000-0002-2795-9751

发表论文 51 篇 · 总被引 472 次 · h-index 12

代表论文

• Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma (2025 · JAMA Surgery · 被引 71)
• Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy (2024 · Phytomedicine · 被引 13)
• Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma (2024 · Journal of Cancer Research and Clinical Oncology · 被引 12)
• Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study (2025 · International Journal of Surgery · 被引 8)
• NEK2 Promotes ESCC Malignant Progression by Inhibiting Cellular Senescence via the FOXM1/c‐Myc/p27 Signaling Pathway (2024 · Molecular Carcinogenesis · 被引 7)
• Prediction model using risk factors associated with anastomotic leakage after minimally invasive esophagectomy (2023 · Pakistan Journal of Medical Sciences · 被引 7)